
Blenrep Approved by US FDA for Use in Treatment of Relapsed Multiple Myeloma
GSK plc announced that the U.S. Food and Drug Administration has approved Blenrep (belantamab mafodotin-blmf) when used along with bortezomib and dexamethasone for adult patients



